The presence of PIK3CA mutation, which activates the PI3K/AKT pathway, and the loss of PTEN expression have been extensively documented in around 33 to 40% of ovarian clear cell carcinomas and 40% of endometrioid carcinomas (21, 22). This evidence concerns the gene PIK3CA and ovarian clear cell cancer.